🏥 Health & Medicine
Madrigal Pharmaceuticals
(MDGL ↗)
madrigalpharma.com
Madrigal makes Rezdiffra — the first and only drug approved for MASH, a serious fatty-liver disease that affects millions of people and had no approved treatment until 2024. Revenue is exploding. It's still losing money, but the loss is shrinking fast. The whole story is a race: scale the first-mover before bigger rivals arrive.
Updated · Q1 2026 · March 2026
6
Chapters
~13
Min read
$1.1B / yr revenue · public since 2016
🌶️🌶️🌶️🌶️
Spice: Ghost (5/5)
More filled = spicier (more aggressive), not "better." Tap a row to see what it means.
What is spice?
Your progress
0 of 6
✦ Reader takes on Madrigal Pharmaceuticals
0 comments
Drop your read. See how others are calling this brief.
No one's weighed in yet. Be the first.
↗ Share Madrigal Pharmaceuticals
↻ The read keeps updating
You're reading the 6 opening chapters. After that, every time Madrigal files a new report, the chapters get updated here.